TrialBMC cancer2025

A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.

Keisuke Baba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.